|
Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: The DEMAND randomized phase II clinical trial. |
|
|
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Lilly; Pfizer; Roche; TERUMO |
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Lilly; Pfizer; Roche; TERUMO |
Research Funding - AstraZeneca; Bayer; Bristol-Myer Squibb; Ipsen; Lilly; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Bristol-Myers Squibb; Celsion; Roche |
|
|
|
Consulting or Advisory Role - Alnylam; Roche |
|
|
Honoraria - Falk Foundation |
Travel, Accommodations, Expenses - Eisai |
|
|
Honoraria - Bayer; Boston Scientific; Sirtex Medical; TERUMO |
Research Funding - Bayer; Boston Scientific; Sirtex Medical; TERUMO |
|
|
No Relationships to Disclose |
|
|
Honoraria - Falk Foundation; Ipsen; Novartis; Roche |
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai |
Research Funding - Lilly; MSD |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Bayer |
Travel, Accommodations, Expenses - Ipsen |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer/Vital; Bristol-Myers Squibb; Incyte; MSD Sharp & Dome GmbH; Roche Pharma AG |
|
|
Consulting or Advisory Role - Abbvie; Bayer/Vital; Boston Scientific; Eisai; Janssen-Cilag; Roche Pharma AG |
Research Funding - Abbvie; Bristol-Myers Squibb; Eisai; Roche Pharma AG |
|
|
Honoraria - Boston Scientific; CSL Behring; Dr. Willmar Schwabe GmbH; Pfizer |
Consulting or Advisory Role - Boston Scientific; CSL Behring; Dr. Willmar Schwabe GmbH; Pfizer |
Travel, Accommodations, Expenses - Bayer; Merz Pharma |
|
|
Honoraria - Bayer; Eisai; Roche |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Roche |
Research Funding - Bayer; Roche |
Travel, Accommodations, Expenses - Roche |
|
|
Honoraria - Bayer; Boston Scientific; Cook Medical; LIAM; Siemens; Sirtex Medical |
Research Funding - Bayer; Sirtex Medical |